tbuckley/cabot-search huggingface dataset:
Abstract 13059: In-vitro Sorbent-Mediated Removal of Edoxaban From Human Plasma and Albumin Solution
Authors: Alexandra A Angheloiu, Yanglan Tan, Cristian I Ruse, Scott Shaffer, George O Angheloiu
Journal: Circulation (2019)

Background: Direct oral anticoagulants are currently the drugs of choice for stroke prophylaxis in patients with atrial fibrillation. While an antidote is currently available - andexanet alfa, its ...
Abstract 2250: Active Cascade Screening in Primary Inherited Arrhythmia Syndromes; Does it Lead to Prophylactic Treatment?
Authors: Nynke Hofman, Hanno L Tan, Irene M van Langen, Arthur A Wilde
Journal: Circulation (2007)

Introduction The congenital long QT syndrome (LQTS), Brugada syndrome (BrS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) are primary inherited cardiac arrhythmia syndromes which may cause syncope and sudden cardiac death in young individuals. After establishing the disease-causing DNA mutation in probands, we actively conducted cascade screening to identify relatives who are also at risk of life-threatening arrhythmias. We studied how often this led to prophylactic treatment. Methods and Results We retrospectively collected data from our Cardiogenetics database and patient records. In 1996–2006, 118 probands with a disease causing mutation in one of the involved genes were identified and 446 relatives were tested positive for the disease causing mutation found in their family. These subjects subsequently underwent cardiologic investigation (ECG, exercise testing, Holter, ajmaline testing, echocardiography, where appropriate). We analyzed the numbers and percentages of identified carriers needing prophylactic treatment. Treatment was deemed necessary based on the results of cardiologic investigation, type of disease, previously reported properties (clinical and/or biophysical) of the mutation, familial occurrence of unexplained sudden death, and age of the subject. Treatment was initiated in 69% (197/285), 9% (5/54) and 71% (76/107) relatives in the LQTS, BrS, and CPVT families, respectively. Twenty-six carriers were lost to follow-up. Treatment included drug treatment (n=244) and implantation of pacemakers (n=26) or ICDs (n=8). Conclusions Cascade screening in families with LQTS, BrS or CPVT, which was based on DNA mutation carriership and subsequent cardiologic investigation, resulted in immediate prophylactic treatment in a substantial proportion of carriers (278/446, 62%), although it varies significantly between the different disease entities.
Effect of oral or topical administration of caffeine on the ATR/Chk1 pathway in the epidermis of UVB-irradiated SKH-1 mice
Authors: Yao-ping Lu, You Rong Lou, Qing Yun Peng, Jian Guo Xie, Paul Nghiem, Allan Conney
Journal: Cancer Research (2007)

3451  In earlier studies, we demonstrated that administration of caffeine to SKH-1 mice inhibited UVB-induced skin carcinogenesis and stimulated UVB-induced apoptosis by p53-dependent and p53-independent mechanisms, and the maximum effect of caffeine on UVB-induced apoptosis was at 6-10 hr post-UVB.  	In the present study, we found that oral administration of caffeine (0.4 mg/ml in the drinking water) to SKH-1 mice for one week prior to UVB irradiation markedly inhibited the UVB-induced increase in the level of p-Chk1 (Ser345) and increased the level of cyclin B1 at 6 hr post-UVB when compared with measurements after UVB alone, but there was little or no effect of caffeine administration on p-Chk2 (Thr68) or p-cyclin B1 (Ser147) as measured by Western blots. Administration of caffeine had little or no effect on these biomarkers in the absence of UVB. A time course study using immunohistochemical assays indicated that irradiation of SKH-1 mice with UVB increased the number of epidermal cells with p-Chk1 (Ser345) and decreased the number of mitotic cells with cyclin B1 between 6-10 hr post-UVB. Oral administration of caffeine for one week stimulated UVB-induced apoptosis, inhibited the UVB-induced increase in p-Chk1 (Ser345) and abrogated the decrease in mitotic cells with cyclin B1 at 6-10 hr post-UVB. Although the caffeine-induced increase in apoptosis after UVB was maximal between 6-10 hr post-UVB and then declined, caffeine continued to affect p-Chk1 (Ser345) and cyclin B1 beyond 10 hr. Topical application of caffeine immediately after UVB irradiation also prematurely increased the number of cyclin B1 positive cells but had little or no effect on p-cyclin B1 (Ser147) at 6 hr post-UVB when compared with measurements after UVB alone. A time course study indicated a dramatic UVB-induced decrease in the percentage of mitotic cells with cyclin B1 in the epidermis of p53 knockout mice between 2-16 hr after UVB. This decrease was abrogated between 6-16 hr post-UVB by topical application of caffeine indicating that caffeine exerts its effect by a p53-independent mechanism. The time course for the stimulatory effect of caffeine for increasing mitotic cells with cyclin B1 in the epidermis of mice treated with UVB paralleled the time course for the formation of apoptotic sunburn cells.  Our studies provide the first evidence that administration of caffeine enhances DNA damage-induced cell killing in vivo in animals by inhibiting the ATR-mediated phosphorylation of Chk1 and increasing the number of epidermal cells undergoing premature mitosis in the presence of cyclin B1. This effect of caffeine results in an early and inappropriate increase in mitotic cells with cyclin B1 which is consistent with the known role for the ATR-Chk1 pathway in preventing premature chromatin condensation. (Supported in part by NIH grant CA114442.)
P46.07 Afatinib-Related Pneumonitis in Metastatic EGFR-Positive NSCLC
Authors: S. Andarini, G.A. Desianti, A. Hanafi, L. Masniari, M. Hafiz, N. Kusumaningtiyas, M. Djajusman, F. Gultom
Journal: Journal of Thoracic Oncology (2021)
MA01.03 PREC Multicentre Restrospective Study: A Preoperative Risk Classification for Synchronous Oligometastatic Non-Small Cell Lung Cancer
Authors: L. Bertolaccini, L. Spaggiari, F. Facciolo, F. Gallina, F. Rea, M. Schiavon, S. Margaritora, M.T. Congedo, M. Lucchi, I. Ceccarelli, M. Alloisio, E. Bottoni, G. Negri, A. Carretta, G. Cardillo, S. Ricciardi, E. Ruffini, L. Costardi, G. Muriana, D. Viggiano, M. Rusca, L. Ventura, G. Marulli, A. De Palma, L. Rosso, P. Mendogni, R. Crisci, A. De Vico, P. Maniscalco, N. Tamburini, F. Puma, S. Ceccarelli, L. Voltolini, S. Bongiolatti, A. Morelli, F. Londero
Journal: Journal of Thoracic Oncology (2021)
Safety of the 4PEPS in Patients With a Very Low Prevalence of Pulmonary Embolism—Need for More Than a Point Estimate—Reply
Authors: Pierre-Marie Roy, Thomas Moumneh, Andrea Penaloza
Journal: JAMA Cardiology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
FP08.03 Outcomes With Multi-Disciplinary Management of Central Lung Tumors Treated With Percutaneous High-Dose-Rate Brachytherapy
Authors: S. Yoon, R. Suh, F. Abtin, D. Moghanaki, S. Genshaft, M. Kamrava, A. Drakaki, S. Liu, P. Venkat, A. Lee, A. Chang
Journal: Journal of Thoracic Oncology (2021)
Local bone metabolism balance regulation via double-adhesive hydrogel for fixing orthopedic implants
Authors: Wei Jiang, Fushan Hou, Yong Gu, Qimanguli Saiding, Pingping Bao, Jincheng Tang, Liang Wu, Chunmao Chen, Cailiang Shen, Catarina Leite Pereira, Marco Sarmento, Bruno Sarmento, Wenguo Cui, Liang Chen
Journal: Bioactive Materials (2021)

The effective osteointegration of orthopedic implants is a key factor for the success of orthopedic surgery. However, local metabolic imbalance around implants under osteoporosis condition could jeopardize the fixation effect. Inspired by the bone structure and the composition around implants under osteoporosis condition, alendronate (A) was grafted onto methacryloyl hyaluronic acid (H) by activating the carboxyl group of methacryloyl hyaluronic acid to be bonded to inorganic calcium phosphate on trabecular bone, which is then integrated with aminated bioactive glass (AB) modified by oxidized dextran (O) for further adhesion to organic collagen on the trabecular bone. The hybrid hydrogel could be solidified on cancellous bone in situ under UV irradiation and exhibits dual adhesion to organic collagen and inorganic apatite, promoting osteointegration of orthopedic implants, resulting in firm stabilization of the implants in cancellous bone areas. In vitro, the hydrogel was evidenced to promote osteogenic differentiation of embryonic mouse osteoblast precursor cells (MC3T3-E1) as well as inhibit the receptor activator of nuclear factor-κ B ligand (RANKL)-induced osteoclast differentiation of macrophages, leading to the upregulation of osteogenic-related gene and protein expression. In a rat osteoporosis model, the bone-implant contact (BIC) of the hybrid hydrogel group increased by 2.77, which is directly linked to improved mechanical stability of the orthopedic implants. Overall, this organic-inorganic, dual-adhesive hydrogel could be a promising candidate for enhancing the stability of orthopedic implants under osteoporotic conditions.
Evaluation of physiological drug resistance of cancer chemotherapy
Authors: Yoshinori Kato, Baasil Okollie, Ming Zhao, Sharyn D. Baker, Zaver M. Bhujwalla, Dmitri Artemov
Journal: Cancer Research (2005)

3804  Introduction: Inadequate tumor vascularization and/or anti-vascular effects of cancer chemotherapy contribute to anticancer drugs’ failure. We pursued physiological drug resistance of cancer chemotherapy in mouse breast cancer models using magnetic resonance imaging (MRI) and spectroscopic imaging (MRSI). Methods: All animal experiments were conducted according to the institutional guidelines. Anesthetized SCID mice with orthotopic MCF-7 breast cancer were immobilized in the probe and maintained under gas anesthesia (Isoflurane 0.5%, 1 l/min). 13C-Labeled-temozolomide ([13C]TMZ) or temozolomide (TMZ: Temodar® capsule), alkylating agent, was used as a model drug. Two hundred microliter of [13C]TMZ (50 mM)/dimethyl-β-cyclodextrin (100 mM) inclusion complex was infused into the mouse via an i.p. catheter. Three-dimensional indirect 1H/13C MRSI was performed with an 8x8x8 matrix for a 16 mm isotropic field of view. During 3D map acquisition, a total of 400 μl of inclusion complex was injected. After completing 13C studies, a GdDTPA bolus was administered and 3D isotropic gradient echo imaging (TE/TR = 15/200 ms) was performed. Tumor growth inhibitory effect of TMZ was evaluated in vivo after oral administration. Plasma and intratumoral concentration of TMZ was measured using high performance liquid chromatography (HPLC). In vitro P-glycoprotein expression and vascular endotherial growth factors (VEGF) expression of MCF-7 cells were also examined by the exposure of TMZ to the cell culture, and detected by flow cytometry and enzyme-linked immunosorbent assay (ELISA), respectively. Effect of TMZ chemotherapy on tumor vasculature was evaluated by dynamic MRI with macromolecular contrast agent. Vascular volume (VV) and permeability surface area (PS) of tumor were defined for control and treated tumors. Results & Discussion: TMZ showed growth inhibitory effect at the primary stage of chemotherapy, but cancer volume was gradually increased at the later stage. VV and PS of cancer were decreased during TMZ chemotherapy for 5 weeks (2 mg/kg/day × 2 doses/week). The concentration of TMZ in the tumor was decreased at the latter stages of chemotherapy, but was not significantly different (p > 0.05). Flow cytometry showed that MCF-7 cells did not express P-glycoproteins during TMZ chemotherapy in this dosing regime. VEGF expression of MCF-7 was suppressed by TMZ at a dose of 50 μg/ml, suggesting one possible mechanism of the anti-vascular TMZ effect within the tumor. Conclusion: This functional MRI study demonstrated that TMZ chemotherapy decreased VV and PS of tumor, suggesting chemotherapy may induce physiological drug resistance by restricting drug delivery to the tumor. HPLC, flow cytometry, and VEGF quantification studies supported the findings from the functional MRI. Acknowledgements: We acknowledge support from NIH RO1 CA097310.
Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease
Authors: Laura Orsatti, Thomas Stiehl, Katharina Dischinger, Roberto Speziale, Pamela Di Pasquale, Edith Monteagudo, Carsten Müller-Tidow, Aleksandar Radujkovic, Peter Dreger, Thomas Luft
Journal: Cell Reports Medicine (2021)

Kynurenine pathway activation and deviation to anthranilic and
Correction: Autophagy receptor CCDC50 modulates STING-mediated interferon response in viral infection and autoimmune disease
Authors: Panpan Hou, Yuxin Lin, Zibo Li, Ruiqing Lu, Yicheng Wang, Tian Tian, Penghui Jia, Xi Zhang, Liu Cao, Zhongwei Zhou, Chunmei Li, Jieruo Gu, Deyin Guo
Journal: Cellular and Molecular Immunology (2021)
Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases
Authors: Xianyuan Xiang, Karin Wind, Thomas Wiedemann, Tanja Blume, Yuan Shi, Nils Briel, Leonie Beyer, Gloria Biechele, Florian Eckenweber, Artem Zatcepin, Sven Lammich, Sara Ribicic, Sabina Tahirovic, Michael Willem, Maximilian Deussing, Carla Palleis, Boris-Stephan Rauchmann, Franz-Josef Gildehaus, Simon Lindner, Charlotte Spitz, Nicolai Franzmeier, Karlheinz Baumann, Axel Rominger, Peter Bartenstein, Sibylle Ziegler, Alexander Drzezga, Gesine Respondek, Katharina Buerger, Robert Perneczky, Johannes Levin, Günter U. Höglinger, Jochen Herms, Christian Haass, Matthias Brendel
Journal: Science Translational Medicine (2021)

2-Deoxy-2-[18F]fluoro-d-glucose positron emission tomography (FDG-PET) is widely used to study cerebral glucose metabolism. Here, we investigated whether the FDG-PET signal is directly influenced by microglial glucose uptake in mouse models and patients with neurodegenerative diseases. Using a recently developed approach for cell sorting after FDG injection, we found that, at cellular resolution, microglia displayed higher glucose uptake than neurons and astrocytes. Alterations in microglial glucose uptake were responsible for both the FDG-PET signal decrease in Trem2-deficient mice and the FDG-PET signal increase in mouse models for amyloidosis. Thus, opposite microglial activation states determine the differential FDG uptake. Consistently, 12 patients with Alzheimer’s disease and 21 patients with four-repeat tauopathies also exhibited a positive association between glucose uptake and microglial activity as determined by 18F-GE-180 18-kDa translocator protein PET (TSPO-PET) in preserved brain regions, indicating that the cerebral glucose uptake in humans is also strongly influenced by microglial activity. Our findings suggest that microglia activation states are responsible for FDG-PET signal alterations in patients with neurodegenerative diseases and mouse models for amyloidosis. Microglial activation states should therefore be considered when performing FDG-PET.
P31.03 The Impact of the COVID-19 Pandemic on a Thoracic Tumor Unit of a Tertiary Hospital in Spain
Authors: L. Cudero, V. Calvo, Y. Garitaonaindia, A. Collazo-Lorduy, F. Franco, M. Martínez-Cutillas, C. Traseira, R. Aguado, M. Provencio
Journal: Journal of Thoracic Oncology (2021)
Abstract 17352: Hand Grip Strength as a Predictor of Exercise Capacity in Coronary Heart Disease
Authors: Cheol Ung Choi, Woohyeun Kim, Se-Hyun Park, Woo-Sub Kim, Won Young Jang, Yoonjee Park, Hong Seog Seo, Chang Gyu Park, Seung-Woon Rha, Eung Ju Kim, Jin Oh Na, Jin Won Kim, Eun Jin Park, Dong Oh Kang
Journal: Circulation (2018)

Introduction: Exercise capacity is related to the prognosis of coronary heart disease (CHD). Recent study have shown that quadriceps strength can be used to predict exercise capacity levels in patients with CHD. Hypothesis: The aim of this study is to determine whether this relationship between muscular strength and exercise capacity is maintained in hand grip strength (HGS). Methods: We studied 310 participants (Age; 62.1 ± 11.5, Men; 77.4 %) who underwent coronary intervention and participated cardiac rehabilitation. Maximal HGS was expressed as absolute value (kg), and relative to bodyweight (%bodyweight). Logistic regression was used to assess the relationship of maximal HGS, age, sex, type of CHD, diabetes, hypertension, renal insufficiency, ejection fraction, body mass index, body weight, waist to hip ratio, and basal metabolic rate with distance walked on 6-minuite walk test (6MWT) and estimated metabolic equivalents (eMETs). Results: Maximal HGS was significantly related to distance walked on 6 MWT (r = 0.40 for %bodyweight, p &lt; 0.001) and eMETs (r = 0.43 for %bodyweight, p &lt; 0.001). Maximal HGS was the strongest predictor of exercise capacity in each distance walked on 6 MWT category. Receiver operating characteristics curves identified maximal HGS of 35.7, 42.0% bodyweight as the best predictive cut offs for 200, and 400 meters, respectively with positive predictive values of 0.64. They also identified HGS of 38.3, and 44.6% bodyweight as the best predictive cut offs for 6 and 8 eMETs, respectively with positive predictive values of 0.70. Conclusions: Maximal HGS is related with distance on 6 MWT and eMETs levels at exercise test in CHD patients. This result suggests that maximal HGS can be used to predict exercise capacity levels. Based on this result, prospective study investigating the association between HGS and clinical outcome of CHD is needed.
Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials
Authors: Evelien M.J. Beelen, Daan Nieboer, Jeanine H.C. Arkenbosch, Miguel D. Regueiro, Jack Satsangi, Sandro Ardizzone, Antonio López-Sanromán, Edoardo Savarino, Alessandro Armuzzi, C. Janneke van der Woude, Annemarie C. de Vries
Journal: Clinical Gastroenterology and Hepatology (2021)

The superiority of anti-TNF-α agents to thiopurines for the prevention of postoperative recurrence of Crohn's disease (CD) after ileocolonic resection remains controversial. In this meta-analysis of individual participant data (IPD), the effect of both strategies was compared and assessed after risk stratification.After a systematic literature search, IPD were requested from randomized controlled trials investigating thiopurines and/or anti-TNF-α agents after ileocolonic resection. Primary outcome was endoscopic recurrence (ER) (Rutgeerts score ≥i2) and secondary outcomes were clinical recurrence (Harvey-Bradshaw Index/Crohn's Disease Activity Index score) and severe ER (Rutgeerts score ≥i3). A fixed effect network meta-analysis was performed. Subgroup effects were assessed and a prediction model was established using Poisson regression models, including sex, smoking, Montreal classification, CD duration, history of prior resection and previous exposure to anti-TNF-α or thiopurines.In the meta-analysis of IPD, 645 participants from 6 studies were included. In the total population, a superior effect was demonstrated for anti-TNF-α compared with thiopurine prophylaxis for ER (relative risk [RR], 0.52; 95% confidence interval [CI], 0.33-0.80), clinical recurrence (RR, 0.50; 95% CI, 0.26-0.96), and severe ER (RR, 0.41; 95% CI, 0.21-0.79). No differential subgroup effects were found for ER. In Poisson regression analysis, previous exposure to anti-TNF-α and penetrating disease behavior were associated with ER risk. The advantage of anti-TNF-α agents as compared with thiopurines was observed in low- and high-risk groups.Anti-TNF-α is superior to thiopurine prophylaxis for the prevention of endoscopic and clinical postoperative CD recurrence after ileocolonic resection. The advantage of anti-TNF-α agents was confirmed in subgroup analysis and after risk stratification.
A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation
Authors: Andrea Schlegel, Marjolein van Reeven, Kristopher Croome, Alessandro Parente, Annalisa Dolcet, Jeannette Widmer, Nicolas Meurisse, Riccardo De Carlis, Amelia Hessheimer, Ina Jochmans, Matteo Mueller, Otto B. van Leeuwen, Amit Nair, Koji Tomiyama, Ahmed Sherif, Mohamed Elsharif, Philipp Kron, Danny van der Helm, Daniel Borja-Cacho, Humberto Bohorquez, Desislava Germanova, Daniele Dondossola, Tiziana Olivieri, Stefania Camagni, Andre Gorgen, Damiano Patrono, Matteo Cescon, Sarah Croome, Rebecca Panconesi, Mauricio Flores Carvalho, Matteo Ravaioli, Juan Carlos Caicedo, George Loss, Valerio Lucidi, Gonzalo Sapisochin, Renato Romagnoli, Wayel Jassem, Michele Colledan, Luciano De Carlis, Giorgio Rossi, Fabrizio Di Benedetto, Charles M. Miller, Bart van Hoek, Magdy Attia, Peter Lodge, Roberto Hernandez-Alejandro, Olivier Detry, Cristiano Quintini, Gabriel C. Oniscu, Constantino Fondevila, Massimo Malagó, Jacques Pirenne, Jan N.M. IJzermans, Robert J. Porte, Philipp Dutkowski, C. Burcin Taner, Nigel Heaton, Pierre-Alain Clavien, Wojciech G. Polak, Paolo Muiesan, Ian P.J. Alwayn, Aad P. van der Berg, Margherita Carbonaro, Marco Claasen, Amna Daud, Vincent E. de Meijer, Herold J. Metselaar, Diethard Monbaliu, Maite Paolucci, Sofie Vets, Erin Winter
Journal: Journal of Hepatology (2021)
P17.01 KEYNOTE-407 China Extension Final Analysis: Pembrolizumab Plus Chemotherapy for the Treatment of Metastatic Squamous NSCLC
Authors: Y. Cheng, L. Zhang, J. Hu, D. Wang, C. Hu, J. Zhou, L. Wu, L. Cao, J. Liu, H. Zhang, H. Sun, Z. Wang, H. Gao, Y. Sun, B. Li, P. Schwarzenberger, L. Paz-Ares
Journal: Journal of Thoracic Oncology (2021)